Clinical Lymphoma, Myeloma & Leukemia最新文献

筛选
英文 中文
Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant. 基于克隆型质谱的可测量残留病在接受自体造血细胞移植的多发性骨髓瘤患者中的预后
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-05-08 DOI: 10.1016/j.clml.2025.04.017
Michael J Slade, Julie Fortier, Abir Khaled, Mark Fiala, Zac McDonald, Mark A Zaydman, Fei Wan, Mark A Schroeder, Keith Stockerl-Goldstein, Liqiang Yang, Ravi Vij
{"title":"Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant.","authors":"Michael J Slade, Julie Fortier, Abir Khaled, Mark Fiala, Zac McDonald, Mark A Zaydman, Fei Wan, Mark A Schroeder, Keith Stockerl-Goldstein, Liqiang Yang, Ravi Vij","doi":"10.1016/j.clml.2025.04.017","DOIUrl":"https://doi.org/10.1016/j.clml.2025.04.017","url":null,"abstract":"<p><strong>Background: </strong>While marrow-based measurable residual disease (MRD) testing for multiple myeloma (MM) is highly associated with outcomes, it is challenging to implement for serial monitoring. Consequently, blood-based MRD testing is desirable.</p><p><strong>Patients and methods: </strong>In this study, we investigated the use of clonotypic mass spectrometry (CT-MS) for blood-based monitoring of M-protein in patients undergoing autologous hematopoietic cell transplant (AHCT). We performed a pilot analysis to assess assay performance, then restricted our analysis of CT-MS as a blood-based MRD assay to patients with 1) banked baseline samples pre-AHCT, 2) no M-protein on serum protein electrophoresis at day +100 post-AHCT and 3) available samples at day +100.</p><p><strong>Results: </strong>One hundred and eleven patients with analyzed, with 94 patients included in the MRD analysis. We derived a proposed threshold for MRD via the minimal P-value approach using two different methods. We found that CT-MS MRD-positivity at day + 100 post-AHCT was significantly associated with worse progression-free survival (PFS) (P < .0001, median PFS 2.5 vs. 8.4 years), with a HR of 3.74 (P = .0002). This association was stable on multi-variable analysis (MVA) adjusting for known risk factors (aHR: 3.68, P = .003). CT-MS MRD-positivity was also associated with significantly worse overall survival (median: 4.95 years vs. not reached, P = .001, HR: 3.95), stable on MVA (aHR: 3.25, P = .01).</p><p><strong>Conclusion: </strong>Our study suggests CT-MS may be a useful tool for blood-based MRD in multiple myeloma (MM).</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guidelines on Management of Multiple Myeloma in the Relapsed/Refractory Setting: The Saudi Myeloma Working Group Guideline. 多发性骨髓瘤复发/难治性治疗指南:沙特骨髓瘤工作组指南
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-05-08 DOI: 10.1016/j.clml.2025.05.005
Ayman Alhejazi, Ghazi S Alotaibi, Abdullah S Al Saleh, Majed Alahmadi, Ibraheem Motabi, Fahad Z Alsharif, Abdullah Alamer, Omar Abduljalil, Imran Tailor, Mohammed Marei, Ahmed S Barefah, Mansour Aljabry, Saud Alhayli, Binyam Usman, Amr Hanbali, Amal Alabdulwahab, Ihab ElHemaidi, Hatem Mahmoud Alahwal, Enas Mutahar, Ahmad Alsaeed
{"title":"Guidelines on Management of Multiple Myeloma in the Relapsed/Refractory Setting: The Saudi Myeloma Working Group Guideline.","authors":"Ayman Alhejazi, Ghazi S Alotaibi, Abdullah S Al Saleh, Majed Alahmadi, Ibraheem Motabi, Fahad Z Alsharif, Abdullah Alamer, Omar Abduljalil, Imran Tailor, Mohammed Marei, Ahmed S Barefah, Mansour Aljabry, Saud Alhayli, Binyam Usman, Amr Hanbali, Amal Alabdulwahab, Ihab ElHemaidi, Hatem Mahmoud Alahwal, Enas Mutahar, Ahmad Alsaeed","doi":"10.1016/j.clml.2025.05.005","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.005","url":null,"abstract":"<p><p>Although the therapeutic options for multiple myeloma have improved survival over time, multiple myeloma tends to relapse and become refractory many times over its course. Unfortunately, the chances of survival of the patients affected diminish with each relapse and consequent line of therapy they receive. The management of multiple myeloma, the therapeutic agents available, and the supportive measures recommended for it have significantly evolved since the Saudi Lymphoma/Myeloma Group published its consensus statement on the management of this disease in 2019. Since updated and clear recommendations adapted to Saudi Arabia are crucial to recognize and appropriately treat different progression patterns in order to counsel patients and healthcare payors, the Saudi Myeloma Working Group has created new recommendations for the management of relapsed and/or refractory multiple myeloma and for the provision of supportive care for clinical specialists in Saudi Arabia to respond to these needs.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blinatumomab Versus Chemotherapy for Post-Induction Consolidation in First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. 布利纳单抗与化疗对b细胞急性淋巴细胞白血病首次复发诱导后巩固:随机临床试验的系统回顾和荟萃分析
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-05-08 DOI: 10.1016/j.clml.2025.05.004
Anderson Matheus Pereira da Silva, Luciano Falcão Carneiro Filho, Mariana Lee Han, Isabelle Rodrigues Menezes, Elizabeth Honorato de Farias, Marianna Leite, Maria da Vitória Santos do Nascimento, Eryvelton de Souza Franco, Maria Bernadete de Sousa Maia
{"title":"Blinatumomab Versus Chemotherapy for Post-Induction Consolidation in First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.","authors":"Anderson Matheus Pereira da Silva, Luciano Falcão Carneiro Filho, Mariana Lee Han, Isabelle Rodrigues Menezes, Elizabeth Honorato de Farias, Marianna Leite, Maria da Vitória Santos do Nascimento, Eryvelton de Souza Franco, Maria Bernadete de Sousa Maia","doi":"10.1016/j.clml.2025.05.004","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.004","url":null,"abstract":"<p><strong>Background: </strong>Relapsed B-cell acute lymphoblastic leukemia (B-ALL) remains a therapeutic challenge, particularly in children, adolescents, and young adults. Blinatumomab, a bispecific T-cell engager targeting CD19-positive leukemic cells, has emerged as an alternative to conventional chemotherapy in post-induction consolidation. This meta-analysis aimed to evaluate its impact on survival outcomes, relapse rates, and treatment-related toxicities.</p><p><strong>Methods: </strong>A systematic review and meta-analysis were conducted following PRISMA guidelines. Randomized controlled trials (RCTs) comparing blinatumomab to chemotherapy as post-induction consolidation therapy in children, adolescents, and young adults with first relapse of standard-risk B-ALL were included. Primary outcomes were disease-free survival (DFS) and overall survival (OS). Secondary outcomes included cumulative incidence of relapse, measurable residual disease (MRD) negativity, hematopoietic stem cell transplantation (HSCT) eligibility, and treatment-related toxicities. Effect sizes were estimated using hazard ratios (HR) and risk ratios (RR) with 95% confidence intervals (CI).</p><p><strong>Results: </strong>Four RCTs including 703 patients were analyzed. Blinatumomab was associated with improved disease-free survival (DFS) (HR 0.59; 95% CI, 0.42-0.81) and OS (HR 0.57; 95% CI, 0.43-0.76), as well as a lower cumulative incidence of relapse (HR 0.26; 95% CI, 0.16-0.41). Referral for HSCT was more frequent in the blinatumomab group (RR 1.43; 95% CI, 1.10-1.85). Furthermore, blinatumomab was associated with a higher rate of measurable residual disease (MRD) negativity at the end of the first consolidation cycle (RR 1.96; 95% CI, 1.40-2.76).</p><p><strong>Conclusion: </strong>Blinatumomab improved survival outcomes and increased the proportion of patients referred for HSCT, supporting its role as post-induction consolidation therapy for relapsed B-ALL in paediatric and young adult populations.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-World Use of carfilzomib-lenalidomide-dexamethasone (KRd) and carfilzomib-dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: A Prospective Multicenter Observational Study. 卡非佐米-来那度胺-地塞米松(KRd)和卡非佐米-地塞米松(Kd)在亚太地区复发/难治性多发性骨髓瘤中的实际应用:一项前瞻性多中心观察研究
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-05-07 DOI: 10.1016/j.clml.2025.05.001
Hang Quach, Kihyun Kim, Raymond Siu Ming Wong, Si Yun Melinda Tan, Ming-Chung Wang, Kopei Chang, Megan Braunlin, Mihaela Talpes, Rani Najdi, Jin Seok Kim
{"title":"Real-World Use of carfilzomib-lenalidomide-dexamethasone (KRd) and carfilzomib-dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: A Prospective Multicenter Observational Study.","authors":"Hang Quach, Kihyun Kim, Raymond Siu Ming Wong, Si Yun Melinda Tan, Ming-Chung Wang, Kopei Chang, Megan Braunlin, Mihaela Talpes, Rani Najdi, Jin Seok Kim","doi":"10.1016/j.clml.2025.05.001","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.001","url":null,"abstract":"<p><strong>Background: </strong>Carfilzomib has demonstrated enhanced efficacy and tolerability in head-to-head clinical trials in patients with relapsed/refractory multiple myeloma (RRMM). However, real-world data on its use and outcomes in the Asia Pacific region remains limited.</p><p><strong>Methods: </strong>This prospective, observational, real-world study included 300 RRMM patients from 29 sites in the Asia Pacific region, who received carfilzomib between July 2019 and June 2023. Data was collected from medical records every 3 months to assess safety and efficacy of two approved regimens: carfilzomib with lenalidomide and dexamethasone (KRd) and carfilzomib with dexamethasone alone (Kd).</p><p><strong>Results: </strong>In KRd cohort, mean age was 62.7 years and median prior lines of therapy (LOT) was 1; in Kd cohort, mean age was 66.3 years with a median LOT of 3 (38% ≥ 4 LOTs). KRd achieved an overall response rate (ORR) of 81.7%, including 53.6% complete responses (CR) and 73.3% very good partial responses (VGPR). In the Kd cohort, ORR was 54.5%, with 27.2% CR and 34.8% VGPR. Median overall survival (OS) was 60.9 months with KRd and 41.6 with Kd; median time to progression (TTP) was 38.5 and 23.7 months, respectively. Grade ≥ 3 adverse events occurred in 18.8% (KRd) and 30.7% (Kd); treatment-related events occurred in 4.0% and 8.8%, leading to discontinuations in 1.1% and 2.6%, respectively.</p><p><strong>Conclusion: </strong>Carfilzomib administered as either KRd or Kd was effective and well tolerated, even in patients with multiple prior LOTs, confirming the safety and response rates observed from clinical trials and real-world studies.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Racial and Socioeconomic Disparities in Cutaneous T-Cell Lymphoma Survival: Insights From the National Cancer Database. 皮肤t细胞淋巴瘤生存的种族和社会经济差异:来自国家癌症数据库的见解。
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-05-07 DOI: 10.1016/j.clml.2025.05.002
Pamela Allen, Yuan Li, Muhammad Hamid, Jessi Zhi
{"title":"Racial and Socioeconomic Disparities in Cutaneous T-Cell Lymphoma Survival: Insights From the National Cancer Database.","authors":"Pamela Allen, Yuan Li, Muhammad Hamid, Jessi Zhi","doi":"10.1016/j.clml.2025.05.002","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.002","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the impacts of treatment related factors, race, and social determinants of health (SDOH) on patients with cutaneous T-cell lymphoma (CTCL) using a hospital-based registry system.</p><p><strong>Methods: </strong>Patients with CTCL diagnosed from 2004 to 2019 were identified from the National Cancer Database (NCDB). Kaplan-Meier analysis, Cox proportional hazards regression models, and Propensity Score Matching (PSM) were conducted to compare the overall survival between white and Black patients.</p><p><strong>Results: </strong>The NCDB cohort (n = 16,189) included 12,266 (75.8%) white patients, 2849 (17.6%) Black patients, and 1074 (6.6%) other races. There were differences in disease, treatment characteristics and SDOH by racial group. Black patients traveled shorter distances (20.3% vs. 28.9%, P < .001) for treatment and were more likely to reside in urban centers. Rurality (HR 1.74 (1.41-2.15)) and treatment at non-academic/research programs (HR 1.21 (95% CI, 1.11-1.31) were associated with increased risks of death. PSM controlling for demographic, disease, SDOH, and treatment-related variables, demonstrated increased risk of death among Black patients (HR:1.20 (95% CI, 1.10-1.30) P < .001).</p><p><strong>Limitations: </strong>Lack of detailed treatment data and misclassified cases may limit the validity of the study.</p><p><strong>Conclusion: </strong>Black patients have a 20% increased risk of death despite controlling for patient, disease, treatment, and social factors.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Minimal Residual Disease Testing for Diffuse Large B Cell Lymphoma. 弥漫性大B细胞淋巴瘤的微小残留病检测。
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-05-07 DOI: 10.1016/j.clml.2025.05.003
Miral Atout, Hadeel Elwaheidi, Rand Maarouf, Abdulwahab A Albabtain, Saud Alhayli, Alfadel Alshaibani, Mahmoud Aljurf, Riad El Fakih
{"title":"Minimal Residual Disease Testing for Diffuse Large B Cell Lymphoma.","authors":"Miral Atout, Hadeel Elwaheidi, Rand Maarouf, Abdulwahab A Albabtain, Saud Alhayli, Alfadel Alshaibani, Mahmoud Aljurf, Riad El Fakih","doi":"10.1016/j.clml.2025.05.003","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.003","url":null,"abstract":"<p><strong>Purpose of review: </strong>Diffuse Large B-cell Lymphoma (DLBCL) is challenging to treat in the context of relapsed and refractory disease. Although approximately 65% of patients are cured with frontline chemotherapy, 35% remain refractory or subsequently relapse following frontline therapy, indicating an urgent need for tailored therapies. This review presents how Minimal Residual Disease (MRD) testing, specifically through the analysis of circulating tumor DNA (ctDNA) in blood, serves as a clinical prognostic factor that may predict relapses and aid in treatment decisions.</p><p><strong>Recent findings: </strong>We describe multiple MRD detection techniques, including droplet digital polymerase chain reaction (DdPCR) and next-generation sequencing (NGS), emphasizing their importance in understanding patients' responses to treatment and in assessing risk levels.</p><p><strong>Summary: </strong>The analysis of ctDNA could be a promising tool to guide physicians to intervene earlier, possibly improving patient outcomes and quality of life. Nonetheless, standardizing these detection techniques and integrating them into clinical practice remain challenging. Future research is crucial to address these barriers, paving the path for greater use of MRD testing in DLBCL management and improving the delivery of effective treatment to patients.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma. 亚巴松司他(TAK-981)联合利妥昔单抗治疗复发/难治性非霍奇金淋巴瘤的I/II期研究
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-05-03 DOI: 10.1016/j.clml.2025.04.020
Sarit E Assouline, Amitkumar Mehta, Walter Hanel, Stéphane Doucet, Patrick B Johnston, AlexeyV Danilov, Brenda W Cooper, Aleksander Chudnovsky, Junyu Ding, Tao Long, Dina Stroopinsky, Deborah Berg, Lapo Alinari
{"title":"Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma.","authors":"Sarit E Assouline, Amitkumar Mehta, Walter Hanel, Stéphane Doucet, Patrick B Johnston, AlexeyV Danilov, Brenda W Cooper, Aleksander Chudnovsky, Junyu Ding, Tao Long, Dina Stroopinsky, Deborah Berg, Lapo Alinari","doi":"10.1016/j.clml.2025.04.020","DOIUrl":"https://doi.org/10.1016/j.clml.2025.04.020","url":null,"abstract":"<p><strong>Background: </strong>Subasumstat (TAK-981) is an investigational, first-in-class, innate immunity enhancer that unlocks innate/adaptive immune responses in target tumor microenvironments through SUMOylation inhibition. Subasumstat enhanced antitumor activity of rituximab in preclinical xenograft models.</p><p><strong>Patients and methods: </strong>This phase I/II study enrolled 34 patients (n = 31, phase I; n = 3, phase II) with CD20+-positive relapsed/refractory non-Hodgkin lymphoma (NHL); patients with indolent NHL had to be refractory to an anti-CD20 antibody. In phase I, patients received intravenous subasumstat (10-120 mg) once weekly (QW) (or twice weekly [BIW], 90 mg only) with intravenous rituximab 375 mg/m<sup>2</sup>.</p><p><strong>Results: </strong>No dose-limiting toxicities were reported, no maximum tolerated dose was identified up to 120 mg QW. Safety outcomes were comparable across QW dosing cohorts; grade ≥ 3 and serious adverse events (AEs) were more common in the BIW cohort. The most common AEs reported during dose escalation were pyrexia (55%), chills (39%), and fatigue (35%). Most AEs were transient and consistent with low-grade flu-like symptoms, indicative of interferon pathway activation. Overall, 8/29 evaluable patients receiving QW dosing achieved an objective response (2 complete responses; 6 partial responses); the overall best response rate was 27.6%. Pharmacodynamic analyses provided evidence of dose-dependent target engagement (subasumstat-SUMO adduct and SUMOylation pathway inhibition) in blood and skin. Induction of a type-I interferon response, demonstrated by gene expression analysis, increased plasma cytokines/chemokine levels, and activation of innate and adaptative immune response was also observed.</p><p><strong>Conclusion: </strong>This study demonstrated a positive benefit-risk profile of subasumstat combined with rituximab in NHL.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SOHO State of the Art Updates and Next Questions | High-Grade B-Cell Lymphomas: Pathologic and Molecular Classification and Therapeutic Implications. 高级别b细胞淋巴瘤:病理和分子分类及治疗意义。
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-04-30 DOI: 10.1016/j.clml.2025.04.021
Rafaella Litvin, Agrima Mian, Sarah L Ondrejka, Brian T Hill
{"title":"SOHO State of the Art Updates and Next Questions | High-Grade B-Cell Lymphomas: Pathologic and Molecular Classification and Therapeutic Implications.","authors":"Rafaella Litvin, Agrima Mian, Sarah L Ondrejka, Brian T Hill","doi":"10.1016/j.clml.2025.04.021","DOIUrl":"https://doi.org/10.1016/j.clml.2025.04.021","url":null,"abstract":"<p><p>High-grade B-cell lymphomas (HGBLs) represent a diverse and aggressive group of neoplasms that lie at the intersection of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL), characterized by unique molecular and clinical features. The recently published International Consensus Classification of Myeloid and Lymphoid Neoplasms (ICC) and the fifth edition WHO Classification of Hematolymphoid Tumors have refined the classification of HGBLs dividing them into subtypes based on clinical, morphologic, and molecular features, with subtle differences in terminology and entity characterization. These lymphomas present significant diagnostic challenges due to overlapping features with DLBCL and BL, and their aggressive clinical course necessitates tailored treatment strategies. Conventional therapies, such as R-CHOP, have demonstrated limited efficacy in these patients, prompting exploration of more intensive regimens and targeted therapies. The identification of molecular biomarkers, such as MYC, BCL2, and/or BCL6 rearrangements, as well as the emerging molecular high-grade (MHG) signature, holds promise for better understanding the pathogenesis of these lymphomas and improving prognostic stratification. Despite advances in classification, no clear consensus exists on optimal treatment approaches, and outcomes remain suboptimal, particularly in cases with isolated MYC translocations. This review aims to summarize the current pathologic and molecular classification of HGBLs, highlight the diagnostic challenges, and explore therapeutic implications, including potential future directions for treatment strategies and molecular-targeted therapies.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac Events in Three Phase 3 Randomized Trials Including Acalabrutinib in Chronic Lymphocytic Leukemia. 阿卡拉布替尼治疗慢性淋巴细胞白血病的三个3期随机试验中的心脏事件
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-04-30 DOI: 10.1016/j.clml.2025.04.018
Rupal O'Quinn, Anthony J Corry, Naghmana Bajwa, Suman Jannuru, Hong Chen, Paulo Miranda, Jennifer R Brown
{"title":"Cardiac Events in Three Phase 3 Randomized Trials Including Acalabrutinib in Chronic Lymphocytic Leukemia.","authors":"Rupal O'Quinn, Anthony J Corry, Naghmana Bajwa, Suman Jannuru, Hong Chen, Paulo Miranda, Jennifer R Brown","doi":"10.1016/j.clml.2025.04.018","DOIUrl":"https://doi.org/10.1016/j.clml.2025.04.018","url":null,"abstract":"<p><strong>Background: </strong>The first-generation Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with CLL but is associated with considerable cardiac toxicity. The more selective second-generation BTK inhibitor acalabrutinib has demonstrated a more favorable cardiovascular safety profile with fewer atrial fibrillation events versus ibrutinib. We performed a comprehensive analysis of cardiac outcomes with acalabrutinib versus active comparators, including ibrutinib, in patients with and without baseline cardiovascular disorders.</p><p><strong>Materials and methods: </strong>Data from three phase 3 trials in CLL (ELEVATE-RR, ELEVATE-TN, ASCEND) were used. Exposure-adjusted incidence rates (EAIR; events/100 person-months) were reported for system organ class \"cardiac disorders\" in patients overall and by number of baseline cardiovascular disorders. All analyses were descriptive. No statistical comparisons were performed.</p><p><strong>Results: </strong>In total, 1362 patients were included; 404 (29.7%) had ≥1 baseline cardiovascular disorder. The overall EAIR of any-grade cardiac disorder events was lower for acalabrutinib versus active comparator in each trial, and acalabrutinib did not increase cardiac events in patients with ≥1 baseline cardiovascular disorder. The EAIR of de novo cardiac disorder events (ie, among patients without baseline cardiovascular disorders) was also lower for acalabrutinib versus active comparator across trials (ELEVATE-RR: 0.34 vs. 0.67 [acalabrutinib vs. ibrutinib], ELEVATE-TN: 0.28 and 0.25 vs. 0.59 [acalabrutinib plus obinutuzumab and acalabrutinib vs. chlorambucil + obinutuzumab], ASCEND: 0.28 vs. 0.44 and 0.54 [acalabrutinib vs. idelalisib plus rituximab and bendamustine plus rituximab]).</p><p><strong>Conclusions: </strong>The EAIRs of cardiac disorder events was relatively low overall with acalabrutinib versus comparators, regardless of the presence of baseline cardiovascular disorders.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of Sponsors on Development of Clinical Research in Multiple Myeloma and AL Amyloidosis: An In-Depth Analysis. 赞助者对多发性骨髓瘤和AL淀粉样变临床研究进展的影响:深入分析。
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-04-29 DOI: 10.1016/j.clml.2025.04.019
Anas Zayad, Nausheen Ahmed, Zahra Mahmoudjafari, Barry S Skikne, Tara Lin, Muhammad U Mushtaq, Joseph McGuirk, Forat Lutfi, Evguenia Bhurtel, Manisha Bhutani, Faiz Anwar, Omar Alkharabsheh, Atrash Shebli, Al-Ola Abdallah
{"title":"The Impact of Sponsors on Development of Clinical Research in Multiple Myeloma and AL Amyloidosis: An In-Depth Analysis.","authors":"Anas Zayad, Nausheen Ahmed, Zahra Mahmoudjafari, Barry S Skikne, Tara Lin, Muhammad U Mushtaq, Joseph McGuirk, Forat Lutfi, Evguenia Bhurtel, Manisha Bhutani, Faiz Anwar, Omar Alkharabsheh, Atrash Shebli, Al-Ola Abdallah","doi":"10.1016/j.clml.2025.04.019","DOIUrl":"https://doi.org/10.1016/j.clml.2025.04.019","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信